SEQ ID NO: 504 of Patent CN110785183A

General Information


DRACP ID  DRACP06787

Peptide Name   SEQ ID NO: 504 of Patent CN110785183A

Sequence  VYEKNGYIYF

Sequence Length  10

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Cancer targeted peptides Immunotherapeutic peptides



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  HLA-B*24

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C64H86N12O17

Absent amino acids  ACDHLMPQRSTW

Common amino acids  Y

Mass  145616

Pl  6.39

Basic residues  1

Acidic residues  1

Hydrophobic residues  3

Net charge  0

Boman Index  -654

Hydrophobicity  -37

Aliphatic Index  68

Half Life 
  Mammalian: 100 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  4470

Absorbance 280nm  496.67

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID CN110785183A

Patent Title  Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, Sclc and Other Cancers

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.